Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26648422 | 0.79 | FFAR3 (0.39) | — | |
| SCHEMBL26648717 | 0.75 | MEN1 (0.42) | BRD4OPRM1OPRK1POLB | |
| SCHEMBL14159065 | 0.73 | BRD4 (0.46) | BRD4OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL2289941 | 0.70 | — | — | |
| SCHEMBL19766 | 0.70 | POLB (0.42) | BRD4OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL1497178 | 0.69 | — | — | |
| SCHEMBL6890988 | 0.68 | ATM (0.42) | BRD4OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL2994530 | 0.68 | BRD4 (0.43) | BRD4OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL28979131 | 0.67 | BRD4 (0.37) | BRD4OPRM1OPRD1OPRK1SLC22A1 | |
| Formic Acid SCHEMBL29488740 | 0.66 | OPRM1 (0.48) | BRD4OPRM1OPRD1OPRK1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4522154-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023220425-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | BRD4 745/4885OPRM1 1254/4885OPRD1 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.